サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747663

トキソイドワクチンの世界市場

Toxoid Vaccines

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
トキソイドワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トキソイドワクチンの世界市場は2030年までに69億米ドルに達する見込み

2024年に56億米ドルと推定されるトキソイドワクチンの世界市場は、分析期間2024-2030年にCAGR 3.5%で成長し、2030年には69億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるジフテリア／破傷風／百日咳ワクチンは、CAGR 3.2%を記録し、分析期間終了時には37億米ドルに達すると予測されます。ジフテリア・破傷風ワクチン分野の成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は15億米ドル、中国はCAGR6.5%で成長予測

米国のトキソイドワクチン市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4％と2.7％と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の「トキソイドワクチン」市場- 主要動向と促進要因のまとめ

現代の予防接種キャンペーンにおいて「トキソイドワクチン」が世界的に重要性を増している理由とは？

トキソイドワクチンは、破傷風やジフテリアのような疾病に対して伝統的に使用されてきましたが、世界の公衆衛生上の課題や人獣共通感染症の脅威が新たに発生する中、再び関連性が高まっています。病原体の生ワクチンや不活化ワクチンとは異なり、トキソイドワクチンは細菌毒素から作られ、無毒化されていますが、免疫原性は保たれており、病気を引き起こすリスクなしに免疫反応を引き起こします。その安全性は、特に乳幼児、妊婦、免疫不全者といった脆弱なグループにおいて高く評価されており、定期的な予防接種に欠かせないものとなっています。さらに、抗菌薬耐性（AMR）に対する懸念が高まっていることから、感染後の治療ではなく、積極的な予防接種によって毒素を介した感染症を予防する取り組みが再活性化しています。開発途上地域では、WHOの予防接種拡大プログラム（EPI）が、特にGaviのような組織とのパートナーシップを通じて、トキソイドワクチンへのアクセス拡大に貢献してきました。各国がユニバーサル・ヘルス・カバレッジを目指す中、トキソイドワクチンは、新しいmRNAやベクターベースのワクチンと比較して、その有効性が証明されており、価格も手頃で、保管も容易であることから、優先的に使用されています。このような公衆衛生の新たな焦点は、一部の地域における世界の出生率の上昇と相まって、小児および妊産婦の予防接種プログラムにおけるトキソイド製剤の安定した需要を引き続き促進しています。

トキソイドワクチンの開発は技術的強化によってどのように変化しているのか？

トキソイドワクチンは古くから確立された原理に基づいているが、バイオテクノロジーとワクチンアジュバントの進歩により、その有効性、安定性、製造期間が大幅に改善されています。最新の組換えDNA技術は、毒素の免疫原性構造を維持しながら安全性を高め、より正確な無毒化プロセスを可能にしました。また、新規アジュバントの開発により、免疫応答が増幅され、必要な投与回数が減少し、防御期間が延長されました。さらに、マイクロニードルパッチや経鼻製剤などの送達メカニズムの革新により、特に農村部や十分なサービスを受けていない地域におけるトキソイドワクチンの入手しやすさと受け入れやすさが向上しています。バイオインフォマティクス・ツールは、抗原構造のモデル化やエピトープ提示の最適化に活用されており、従来の破傷風やジフテリアの標的を超えた他の細菌毒素に対応する可能性のある次世代トキソイドベースの製剤への道を開いています。さらに、自動発酵・精製システムを備えた大規模な生物製造プラットフォームは、製造コストを削減し、バッチのスケーラビリティを向上させています。このような技術的進歩は、トキソイドワクチンの性能と到達範囲を向上させるだけでなく、潜在的なバイオテロの脅威や、毒素を分泌する病原体による突然のアウトブレイクへの迅速な対応を可能にしています。

トキソイドワクチンは世界の健康格差と闘う鍵になるか？

トキソイドワクチンは、特にインフラやヘルスケアの提供が制約されがちな中低所得国（LMICs）において、世界ヘルスの格差を埋める上で極めて重要な役割を果たします。標準的なコールドチェーン条件下での安定性と低い製造コストは、資源が限られた地域での集団予防接種に非常に適しています。ユニセフやGaviなどの組織は、こうした利点を活かし、全国的な予防接種日や学校でのワクチン・キャンペーンに資金を提供し、促進しています。人道危機地域や難民キャンプでは、特に衛生環境や創傷ケアが十分でない環境において、予防可能でありながら致命的となりうる疾病の発生を予防するために、トキソイドワクチンが配備されることが多いです。市場参入企業もまた、特に南アジアやアフリカにおいて、技術移転協定やWHOの事前認定プログラムに支えられた地元製薬企業の参入が増加しています。こうした地域メーカーは、高コストの輸入品への依存を減らしつつ、国内需要を満たすのに役立っています。さらに、プライマリーヘルスケアや母子保健プログラムへの政府投資の増加により、トキソイドワクチン接種が定期検診に組み込まれ、市場への浸透がさらに進んでいます。世界の保健機関が公平なアクセスを重視する中、トキソイドワクチンは、毒素を介する細菌性疾患による罹患率や死亡率を減少させる取り組みにおいて重要なツールとして浮上しています。

トキソイドワクチン市場の成長はいくつかの要因によって牽引されている...

トキソイドワクチン市場の成長は、技術の洗練、人口動態の変化、公衆衛生の優先事項の進化に関連するいくつかの要因によって牽引されています。最も影響力のある要因の一つは、世界の出生率の安定であり、トキソイドワクチンのコアターゲットである破傷風やジフテリアに対する小児予防接種の高い需要を支えています。先進国、新興経済諸国ともに、政府主導の予防接種イニシアチブと就学要件が、市場の安定的な取り込みをさらに確実なものにしています。妊産婦の健康分野では、新生児破傷風撲滅の重要性が高まっていることから、多くの国が、特に農村部において、妊婦へのトキソイドワクチン接種を定期的に実施しています。技術面では、改良されたアジュバント・システムや組換え型無毒化などのワクチン製剤の進歩により、トキソイドワクチンはより効果的で反応しにくいものとなっています。より優れたバイオ製造インフラと規制当局の支援によって可能になった地域製造業者の拠点拡大により、サプライチェーンの安定性が向上し、コストが削減されました。AMRに関連する病原体を含め、毒素産生病原体がもたらすリスクに対する意識の高まりも、ヘルスケア政策立案者にトキソイドに基づく予防戦略の強化を促しています。さらに、健康の公平性と疾病の撲滅に焦点を当てた世界のイニシアティブが進行中であり、トキソイドワクチンの展開に多額の資金と後方支援が継続的に割り当てられているため、市場は地域を問わず活気と回復力を維持しています。

セグメント

ワクチンタイプ（ジフテリア/破傷風/百日咳,ジフテリア&破傷風,その他のワクチンタイプ）;エンドユーザー（病院,専門センター,政府機関,その他のエンドユーザー）

調査対象企業の例（注目の42社）

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BB-NCIPD Ltd.
  • Bharat Biotech
  • Biological E Limited
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • GlaxoSmithKline plc（GSK）
  • JN-International Medical Corporation
  • MassBiologics
  • Merck & Co., Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products
  • Takeda Pharmaceutical Company Ltd.
  • Valneva SE
  • VBI Vaccines Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後の7月にも無料アップデートをお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35896

Global Toxoid Vaccines Market to Reach US$6.9 Billion by 2030

The global market for Toxoid Vaccines estimated at US$5.6 Billion in the year 2024, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Diphtheria / Tetanus / Pertussis Vaccine, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Diphtheria & Tetanus Vaccine segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 6.5% CAGR

The Toxoid Vaccines market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global "Toxoid Vaccines" Market - Key Trends & Drivers Summarized

Why Are Toxoid Vaccines Regaining Global Relevance in Modern Immunization Campaigns?

Toxoid vaccines, traditionally used against diseases like tetanus and diphtheria, are experiencing renewed relevance amid global public health challenges and emerging zoonotic threats. Unlike live or inactivated pathogen vaccines, toxoid vaccines are created from bacterial toxins that are rendered non-toxic but still immunogenic, triggering an immune response without risk of causing the disease. Their safety profile, particularly in vulnerable groups such as infants, pregnant women, and immunocompromised individuals, continues to make them indispensable in routine immunization schedules. Additionally, rising concerns over antimicrobial resistance (AMR) have reinvigorated efforts to prevent toxin-mediated infections through proactive immunization rather than post-infection treatment. In developing regions, the WHO’s Expanded Program on Immunization (EPI) has been instrumental in increasing access to toxoid vaccines, particularly through partnerships with organizations like Gavi. As countries strive for universal health coverage, toxoid vaccines are being prioritized for their proven efficacy, affordability, and ease of storage compared to newer mRNA or vector-based vaccines. This renewed public health focus-combined with rising global birth rates in some regions-continues to fuel steady demand for toxoid formulations within pediatric and maternal immunization programs.

How Are Technological Enhancements Reshaping Toxoid Vaccine Development?

Though toxoid vaccines are based on long-established principles, advancements in biotechnology and vaccine adjuvants are significantly improving their efficacy, stability, and production timelines. Modern recombinant DNA technologies have enabled more precise detoxification processes, enhancing safety while preserving the immunogenic structure of the toxin. The development of novel adjuvants has also amplified immune responses, reducing the number of doses required and extending protection duration. Moreover, innovations in delivery mechanisms, such as micro-needle patches and intranasal formulations, are increasing the accessibility and acceptance of toxoid vaccines, particularly in rural and underserved areas. Bioinformatics tools are being utilized to model antigen structures and optimize epitope presentation, paving the way for next-generation toxoid-based formulations that may address other bacterial toxins beyond the conventional tetanus and diphtheria targets. Furthermore, large-scale biomanufacturing platforms-equipped with automated fermentation and purification systems-are reducing production costs and increasing batch scalability. These technological strides are not only improving the performance and reach of toxoid vaccines but also allowing for faster responses to potential bioterror threats and sudden outbreaks caused by toxin-secreting pathogens.

Could Toxoid Vaccines Become the Key to Combating Global Health Inequities?

Toxoid vaccines play a pivotal role in bridging global health gaps, particularly in low- and middle-income countries (LMICs) where infrastructure and healthcare delivery are often constrained. Their stability under standard cold chain conditions and low production costs make them highly suitable for mass immunization drives in regions with limited resources. Organizations such as UNICEF and Gavi are leveraging these advantages to fund and facilitate national immunization days and school-based vaccine campaigns. In humanitarian crisis zones and refugee camps, toxoid vaccines are often deployed to prevent outbreaks of preventable yet potentially fatal diseases, especially in settings where sanitation and wound care are suboptimal. The market is also witnessing increased participation from local pharmaceutical firms, especially in South Asia and Africa, supported by technology transfer agreements and WHO prequalification programs. These regional manufacturers help meet domestic demand while reducing dependency on high-cost imports. Additionally, increasing government investments in primary healthcare and maternal-child health programs have embedded toxoid vaccinations into routine check-ups, further expanding their market penetration. With global health organizations emphasizing equitable access, toxoid vaccines are emerging as a critical tool in efforts to reduce morbidity and mortality from toxin-mediated bacterial diseases.

The Growth in the Toxoid Vaccines Market Is Driven by Several Factors…

The growth in the toxoid vaccines market is driven by several factors related to technological refinement, demographic shifts, and evolving public health priorities. One of the most influential drivers is the consistent global birth rate, which sustains high demand for pediatric immunization against tetanus and diphtheria-core targets of toxoid vaccines. Government-led vaccination initiatives and school-entry requirements in both developed and emerging economies further ensure stable market uptake. In maternal health, the rising emphasis on neonatal tetanus elimination has prompted many nations to adopt routine toxoid vaccination for pregnant women, especially in rural areas. From a technological perspective, advances in vaccine formulation-such as improved adjuvant systems and recombinant detoxification-have made toxoid vaccines more effective and less reactogenic. The expanding footprint of regional manufacturers, enabled by better biomanufacturing infrastructure and regulatory support, has improved supply chain stability and reduced costs. Rising awareness of the risks posed by toxin-producing pathogens, including those linked to AMR, is also prompting healthcare policymakers to reinforce toxoid-based preventive strategies. Furthermore, ongoing global initiatives focused on health equity and disease eradication continue to allocate significant funding and logistical support to toxoid vaccine deployment, ensuring the market remains vibrant and resilient across geographies.

SCOPE OF STUDY:

The report analyzes the Toxoid Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus, Other Vaccine Types); End-Use (Hospitals, Specialty Centers, Governments Organization, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BB-NCIPD Ltd.
  • Bharat Biotech
  • Biological E Limited
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • GlaxoSmithKline plc (GSK)
  • JN-International Medical Corporation
  • MassBiologics
  • Merck & Co., Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products
  • Takeda Pharmaceutical Company Ltd.
  • Valneva SE
  • VBI Vaccines Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Toxoid Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Tetanus and Diphtheria Infections Spurs Global Demand
    • Increasing Immunization Coverage Across Emerging Economies Expands Market Opportunity
    • Government Vaccination Campaigns Strengthen the Business Case for Toxoid Vaccine Production
    • Advancements in Adjuvant Technologies Drive Next-Generation Vaccine Development
    • Growing Anti-Microbial Resistance Throws the Spotlight on Preventive Healthcare Solutions
    • Favorable Regulatory Approvals Accelerate Global Market Entry and Accessibility
    • Aging Population and Immunosenescence Drive Demand for Booster Immunizations
    • Inclusion in National Immunization Programs Expands Addressable Patient Base
    • Public-Private Collaborations Boost Innovation in Delivery Systems and Formulations
    • Cold Chain Improvements in Developing Countries Sustain Growth of Toxoid Vaccines
    • Increasing Awareness of Pediatric and Maternal Immunization Spurs Market Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Toxoid Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Diphtheria / Tetanus / Pertussis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diphtheria & Tetanus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diphtheria & Tetanus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diphtheria & Tetanus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Specialty Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Governments Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Governments Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Governments Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Toxoid Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Toxoid Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Toxoid Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Toxoid Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Toxoid Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Toxoid Vaccines by Vaccine Type - Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Toxoid Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Diphtheria / Tetanus / Pertussis, Diphtheria & Tetanus and Other Vaccine Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Toxoid Vaccines by End-Use - Hospitals, Specialty Centers, Governments Organization and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Toxoid Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Centers, Governments Organization and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION